ATE449106T1 - Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselben - Google Patents

Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselben

Info

Publication number
ATE449106T1
ATE449106T1 AT97916024T AT97916024T ATE449106T1 AT E449106 T1 ATE449106 T1 AT E449106T1 AT 97916024 T AT97916024 T AT 97916024T AT 97916024 T AT97916024 T AT 97916024T AT E449106 T1 ATE449106 T1 AT E449106T1
Authority
AT
Austria
Prior art keywords
fibroblast
applications
protein alpha
activate protein
isolated dimeric
Prior art date
Application number
AT97916024T
Other languages
English (en)
Inventor
Rainer Zimmerman
John Park
Wolfgang Rettig
Lloyd Old
Original Assignee
Ludwig Inst Cancer Res
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Boehringer Ingelheim Int filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE449106T1 publication Critical patent/ATE449106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
AT97916024T 1996-03-18 1997-03-12 Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselben ATE449106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/619,280 US5767242A (en) 1994-04-20 1996-03-18 Isolated dimeric fibroblast activation protein alpha, and uses thereof
PCT/US1997/004215 WO1997034927A1 (en) 1996-03-18 1997-03-12 Isolated dimeric fibroblast activation protein alpha, and uses thereof

Publications (1)

Publication Number Publication Date
ATE449106T1 true ATE449106T1 (de) 2009-12-15

Family

ID=24481231

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97916024T ATE449106T1 (de) 1996-03-18 1997-03-12 Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselben

Country Status (23)

Country Link
US (2) US5767242A (de)
EP (1) EP0960127B1 (de)
JP (1) JP4102441B2 (de)
KR (1) KR20000064655A (de)
CN (1) CN1214052A (de)
AT (1) ATE449106T1 (de)
AU (1) AU729369B2 (de)
BG (1) BG102781A (de)
BR (1) BR9708100A (de)
CA (1) CA2242342C (de)
CZ (1) CZ299698A3 (de)
DE (1) DE69739665D1 (de)
DK (1) DK0960127T3 (de)
EE (1) EE03693B1 (de)
ES (1) ES2334183T3 (de)
HU (1) HUP0104468A3 (de)
IL (1) IL125124A0 (de)
NO (1) NO984298D0 (de)
NZ (2) NZ331758A (de)
PL (1) PL328947A1 (de)
SK (1) SK126798A3 (de)
TR (1) TR199801845T2 (de)
WO (1) WO1997034927A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP1806138A1 (de) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor präparate enthaltend boroprolin verbindungen
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU781897B2 (en) * 1999-05-25 2005-06-23 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US20030092890A1 (en) * 1999-07-28 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US7691967B2 (en) 2002-04-30 2010-04-06 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
WO2004004661A2 (en) * 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US20080057491A1 (en) * 2003-02-07 2008-03-06 Mckee Patrick A Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
US7309774B2 (en) 2003-02-07 2007-12-18 The Board Of Regents Of The University Of Oklahoma Antiplasmin cleaving enzyme
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
WO2005071073A1 (en) * 2004-01-09 2005-08-04 Point Therapeutics, Inc. Fap compositions and the use thereof for immunomodulation
US20090010919A1 (en) * 2004-07-29 2009-01-08 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Fibroblast Activation Protein (Fap)
DK1794586T3 (da) * 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
EP1812458A2 (de) * 2004-10-27 2007-08-01 Wen-Tien Chen Verfahren und zusammensetzungen zur desaktivierung von seprase
PL1824991T3 (pl) 2004-11-24 2016-08-31 Techlab Inc Urządzenie oraz sposób do wykrywania analitów
US8067248B2 (en) 2005-12-14 2011-11-29 Luwig Institute for Cancer Research Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
PT2035581E (pt) * 2006-06-21 2012-12-06 Scripps Research Inst Composição de adn contra o antigénio do estroma tumoral fap e métodos de utilização desta
EP2400976B1 (de) 2009-02-27 2016-12-14 Trustees Of Tufts College Sanfte proteasehemmer und pro-sanfte formen
CA2896337C (en) * 2012-12-28 2022-08-23 Life Sciences Research Partners Vzw Minimally toxic prodrugs
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
CN106573073B (zh) 2014-06-13 2021-09-28 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
CN105859866B (zh) * 2016-05-27 2019-08-13 郑州大学 Fap来源的抗肿瘤ctl表位肽p265及其应用
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP3624841A4 (de) 2017-06-15 2021-01-27 Cancer Advances, Inc., Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2022136586A1 (en) 2020-12-22 2022-06-30 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320734C (en) * 1986-02-04 1993-07-27 Suntory Limited Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
US5587299A (en) * 1994-04-20 1996-12-24 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof

Also Published As

Publication number Publication date
CZ299698A3 (cs) 1999-01-13
JP4102441B2 (ja) 2008-06-18
EP0960127A1 (de) 1999-12-01
SK126798A3 (en) 1999-05-07
US5767242A (en) 1998-06-16
IL125124A0 (en) 1999-01-26
CN1214052A (zh) 1999-04-14
ES2334183T3 (es) 2010-03-05
JP2000507100A (ja) 2000-06-13
PL328947A1 (en) 1999-03-01
HUP0104468A3 (en) 2004-10-28
AU2330297A (en) 1997-10-10
KR20000064655A (ko) 2000-11-06
CA2242342C (en) 2013-05-14
CA2242342A1 (en) 1997-09-25
AU729369B2 (en) 2001-02-01
NZ331758A (en) 2000-01-28
US5965373A (en) 1999-10-12
NO984298L (no) 1998-09-17
DK0960127T3 (da) 2010-03-29
WO1997034927A1 (en) 1997-09-25
NO984298D0 (no) 1998-09-17
BG102781A (en) 1999-09-30
DE69739665D1 (de) 2009-12-31
EE9800306A (et) 1999-02-15
TR199801845T2 (xx) 1998-12-21
EP0960127B1 (de) 2009-11-18
EE03693B1 (et) 2002-04-15
EP0960127A4 (de) 2004-09-08
BR9708100A (pt) 2000-01-04
NZ335543A (en) 2001-03-30
HUP0104468A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
ATE449106T1 (de) Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselben
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ES2195970T3 (es) L-ribavirina y usos de la misma.
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ID23374A (id) Halogenopirimidin
DE69840474D1 (de) Temperaturunempfindlicher siliziumoszillator und daraus erzeugte präzesionsspannungsreferenz
DE69832158D1 (de) Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
NO964966D0 (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
NO971875L (no) Cathepsin 02 protease
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
AR016981A2 (es) Polipeptidos sinteticos
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
BG101787A (en) Aprotinine options having improved properties
ES2175356T3 (es) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares.
DK1012175T3 (da) Peptid med affinitet til koagulationsfaktor VIII
TR199802504T2 (xx) N�rotoksik yaralanmalar�n tedavisi i�in bukminsterflirin kullan�lmas�.
DK0942992T3 (da) O-fucosyltransferase
EP0826764A3 (de) Verwendung substituierter 2-Acetylbenzofurane als Riechstoffe
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
ATE313627T1 (de) Frazzled nukleotidsequenzen, expressionsprodukte, zusammensetzungen und verwendungen
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
BG102937A (en) Zona pelucida proteins as contraceptives
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
ES1033850Y (es) Dispositivo para la aplicacion de cremas, bronceadores y similares.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0960127

Country of ref document: EP